Excessive daytime sleepiness Market Research Report Information By Diseases (Obstructive Sleep Apnea (OSA), Narcolepsy), By Treatment (Devices, Therapeutic Drugs (Stimulants, Anti-Depressants, Amphetamine salts, Sodium oxybate)) By Distribution channels (Hospitals & Sleep Laboratories, Home Care Settings), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market Forecast Till 2032

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET INTRODUCTION

2.1. Definition

2.2. Scope of the Study

2.2.1. Research Objective

2.2.2. Assumptions

2.2.3. Limitations

3. RESEARCH METHODOLOGY

3.1. Overview

3.2. Data Mining

3.3. Secondary Research

3.4. Primary Research

3.4.1. Primary Interviews and Information Gathering Process

3.4.2. Breakdown of Primary Respondents

3.5. Forecasting Model

3.6. Market Size Estimation

3.6.1. Bottom-Up Approach

3.6.2. Top-Down Approach

3.7. Data Triangulation

3.8. Validation

4. MARKET DYNAMICS

4.1. Overview

4.2. Drivers

4.3. Restraints

4.4. Opportunities

5. MARKET FACTOR ANALYSIS

5.1. Value Chain Analysis

5.2. Porter’s Five Forces Analysis

5.2.1. Bargaining Power of Suppliers

5.2.2. Bargaining Power of Buyers

5.2.3. Threat of New Entrants

5.2.4. Threat of Substitutes

5.2.5. Intensity of Rivalry

5.3. COVID-19 Impact Analysis

5.3.1. Market Impact Analysis

5.3.2. Regional Impact

5.3.3. Opportunity and Threat Analysis

6. EXCESSIVE DAYTIME SLEEPINESS MARKET, BY DISEASES

6.1. Overview

6.2. Obstructive Sleep Apnea (OSA)

6.3. Narcolepsy

7. EXCESSIVE DAYTIME SLEEPINESS MARKET, BY TREATMENT

7.1. Overview

7.2. Devices

7.3. Therapeutic Drugs (Stimulants, Anti-Depressants, Amphetamine salts, Sodium oxybate)

8. EXCESSIVE DAYTIME SLEEPINESS MARKET, BY DISTRIBUTION CHANNELS

8.1. Overview

8.2. Hospitals & Sleep Laboratories

8.3. Home Care Settings

9. EXCESSIVE DAYTIME SLEEPINESS MARKET, BY REGION

9.1. Overview

9.1. North America

9.1.1. US

9.1.2. Canada

9.2. Europe

9.2.1. Germany

9.2.2. France

9.2.3. UK

9.2.4. Italy

9.2.5. Spain

9.2.6. Rest of Europe

9.3. Asia-Pacific

9.3.1. China

9.3.2. India

9.3.3. Japan

9.3.4. South Korea

9.3.5. Australia

9.3.6. Rest of Asia-Pacific

9.4. Rest of the World

9.4.1. Middle East

9.4.2. Africa

9.4.3. Latin America

10. COMPETITIVE LANDSCAPE

10.1. Overview

10.2. Competitive Analysis

10.3. Market Share Analysis

10.4. Major Growth Strategy in the Excessive daytime sleepiness Market,

10.5. Competitive Benchmarking

10.6. Leading Players in Terms of Number of Developments in the Excessive daytime sleepiness Market,

10.7. Key developments and Growth Strategies

10.7.1. New Product Launch/Service Deployment

10.7.2. Merger & Acquisitions

10.7.3. Joint Ventures

10.8. Major Players Financial Matrix

10.8.1. Sales & Operating Income, 2022

10.8.2. Major Players R&D Expenditure. 2022

11. COMPANY PROFILES

11.1. Teva Pharmaceutical Industries Ltd.

11.1.1. Company Overview

11.1.2. Financial Overview

11.1.3. Products Offered

11.1.4. Key Developments

11.1.5. SWOT Analysis

11.1.6. Key Strategies

11.2. GE Healthcare

11.2.1. Company Overview

11.2.2. Financial Overview

11.2.3. Products Offered

11.2.4. Key Developments

11.2.5. SWOT Analysis

11.2.6. Key Strategies

11.3. Jazz Pharmaceuticals

11.3.1. Company Overview

11.3.2. Financial Overview

11.3.3. Products Offered

11.3.4. Key Developments

11.3.5. SWOT Analysis

11.3.6. Key Strategies

11.4. Compumedics

11.4.1. Company Overview

11.4.2. Financial Overview

11.4.3. Products Offered

11.4.4. Key Developments

11.4.5. SWOT Analysis

11.4.6. Key Strategies

11.5. Fisher & Paykel Healthcare

11.5.1. Company Overview

11.5.2. Financial Overview

11.5.3. Products Offered

11.5.4. Key Developments

11.5.5. SWOT Analysis

11.5.6. Key Strategies

11.6. BIOPROJET

11.6.1. Company Overview

11.6.2. Financial Overview

11.6.3. Products Offered

11.6.4. Key Developments

11.6.5. SWOT Analysis

11.6.6. Key Strategies

11.7. BMC Medical Co. Ltd.

11.7.1. Company Overview

11.7.2. Financial Overview

11.7.3. Products Offered

11.7.4. Key Developments

11.7.5. SWOT Analysis

11.7.6. Key Strategies

11.8. AVADEL PHARMACEUTICALS PLC

11.8.1. Company Overview

11.8.2. Financial Overview

11.8.3. Products Offered

11.8.4. Key Developments

11.8.5. SWOT Analysis

11.8.6. Key Strategies

11.9. Cadwell Laboratories Inc. Ltd

11.9.1. Company Overview

11.9.2. Financial Overview

11.9.3. Products Offered

11.9.4. Key Developments

11.9.5. SWOT Analysis

11.9.6. Key Strategies

11.10. GlaxoSmithKline plc

11.10.1. Company Overview

11.10.2. Financial Overview

11.10.3. Products Offered

11.10.4. Key Developments

11.10.5. SWOT Analysis

11.10.6. Key Strategies

11.11. Braebon Medical Corporation

11.11.1. Company Overview

11.11.2. Financial Overview

11.11.3. Products Offered

11.11.4. Key Developments

11.11.5. SWOT Analysis

11.11.6. Key Strategies

11.12. Pfizer

11.12.1. Company Overview

11.12.2. Financial Overview

11.12.3. Products Offered

11.12.4. Key Developments

11.12.5. SWOT Analysis

11.12.6. Key Strategies

12. APPENDIX

12.1. References

12.2. Related Reports

LIST OF TABLES

TABLE 1 EXCESSIVE DAYTIME SLEEPINESS MARKET, SYNOPSIS, 2018-2032

TABLE 2 EXCESSIVE DAYTIME SLEEPINESS MARKET, ESTIMATES & FORECAST, 2018-2032 (USD BILLION)

TABLE 3 EXCESSIVE DAYTIME SLEEPINESS MARKET, BY DISEASES, 2018-2032 (USD BILLION)

TABLE 4 EXCESSIVE DAYTIME SLEEPINESS MARKET, BY TREATMENT, 2018-2032 (USD BILLION)

TABLE 5 EXCESSIVE DAYTIME SLEEPINESS MARKET, BY DISTRIBUTION CHANNELS, 2018-2032 (USD BILLION)

TABLE 6 NORTH AMERICA: EXCESSIVE DAYTIME SLEEPINESS MARKET, BY DISEASES, 2018-2032 (USD BILLION)

TABLE 7 NORTH AMERICA: EXCESSIVE DAYTIME SLEEPINESS MARKET, BY TREATMENT, 2018-2032 (USD BILLION)

TABLE 8 NORTH AMERICA: EXCESSIVE DAYTIME SLEEPINESS MARKET, BY DISTRIBUTION CHANNELS, 2018-2032 (USD BILLION)

TABLE 9 US: EXCESSIVE DAYTIME SLEEPINESS MARKET, BY DISEASES, 2018-2032 (USD BILLION)

TABLE 10 US: EXCESSIVE DAYTIME SLEEPINESS MARKET, BY TREATMENT, 2018-2032 (USD BILLION)

TABLE 11 US: EXCESSIVE DAYTIME SLEEPINESS MARKET, BY DISTRIBUTION CHANNELS, 2018-2032 (USD BILLION)

TABLE 12 CANADA: EXCESSIVE DAYTIME SLEEPINESS MARKET, BY DISEASES, 2018-2032 (USD BILLION)

TABLE 13 CANADA: EXCESSIVE DAYTIME SLEEPINESS MARKET, BY TREATMENT, 2018-2032 (USD BILLION)

TABLE 14 CANADA: EXCESSIVE DAYTIME SLEEPINESS MARKET, BY DISTRIBUTION CHANNELS, 2018-2032 (USD BILLION)

TABLE 1 EUROPE: EXCESSIVE DAYTIME SLEEPINESS MARKET, BY DISEASES, 2018-2032 (USD BILLION)

TABLE 2 EUROPE: EXCESSIVE DAYTIME SLEEPINESS MARKET, BY TREATMENT, 2018-2032 (USD BILLION)

TABLE 3 EUROPE: EXCESSIVE DAYTIME SLEEPINESS MARKET, BY DISTRIBUTION CHANNELS, 2018-2032 (USD BILLION)

TABLE 4 GERMANY: EXCESSIVE DAYTIME SLEEPINESS MARKET, BY DISEASES, 2018-2032 (USD BILLION)

TABLE 5 GERMANY: EXCESSIVE DAYTIME SLEEPINESS MARKET, BY TREATMENT, 2018-2032 (USD BILLION)

TABLE 6 GERMANY: EXCESSIVE DAYTIME SLEEPINESS MARKET, BY DISTRIBUTION CHANNELS, 2018-2032 (USD BILLION)

TABLE 7 FRANCE: EXCESSIVE DAYTIME SLEEPINESS MARKET, BY DISEASES, 2018-2032 (USD BILLION)

TABLE 8 FRANCE: EXCESSIVE DAYTIME SLEEPINESS MARKET, BY TREATMENT, 2018-2032 (USD BILLION)

TABLE 9 FRANCE: EXCESSIVE DAYTIME SLEEPINESS MARKET, BY DISTRIBUTION CHANNELS, 2018-2032 (USD BILLION)

TABLE 10 ITALY: EXCESSIVE DAYTIME SLEEPINESS MARKET, BY DISEASES, 2018-2032 (USD BILLION)

TABLE 11 ITALY: EXCESSIVE DAYTIME SLEEPINESS MARKET, BY TREATMENT, 2018-2032 (USD BILLION)

TABLE 12 ITALY: EXCESSIVE DAYTIME SLEEPINESS MARKET, BY DISTRIBUTION CHANNELS, 2018-2032 (USD BILLION)

TABLE 13 SPAIN: EXCESSIVE DAYTIME SLEEPINESS MARKET, BY DISEASES, 2018-2032 (USD BILLION)

TABLE 14 SPAIN: EXCESSIVE DAYTIME SLEEPINESS MARKET, BY TREATMENT, 2018-2032 (USD BILLION)

TABLE 15 SPAIN: EXCESSIVE DAYTIME SLEEPINESS MARKET, BY DISTRIBUTION CHANNELS, 2018-2032 (USD BILLION)

TABLE 16 UK: EXCESSIVE DAYTIME SLEEPINESS MARKET, BY DISEASES, 2018-2032 (USD BILLION)

TABLE 17 UK: EXCESSIVE DAYTIME SLEEPINESS MARKET, BY TREATMENT, 2018-2032 (USD BILLION)

TABLE 18 UK: EXCESSIVE DAYTIME SLEEPINESS MARKET, BY DISTRIBUTION CHANNELS, 2018-2032 (USD BILLION)

TABLE 19 REST OF EUROPE: EXCESSIVE DAYTIME SLEEPINESS MARKET, BY DISEASES, 2018-2032 (USD BILLION)

TABLE 20 REST OF EUROPE: EXCESSIVE DAYTIME SLEEPINESS MARKET, BY TREATMENT, 2018-2032 (USD BILLION)

TABLE 21 REST OF EUROPE: EXCESSIVE DAYTIME SLEEPINESS MARKET, BY DISTRIBUTION CHANNELS, 2018-2032 (USD BILLION)

TABLE 22 ASIA-PACIFIC: EXCESSIVE DAYTIME SLEEPINESS MARKET, BY DISEASES, 2018-2032 (USD BILLION)

TABLE 23 ASIA-PACIFIC: EXCESSIVE DAYTIME SLEEPINESS MARKET, BY TREATMENT, 2018-2032 (USD BILLION)

TABLE 24 ASIA-PACIFIC: EXCESSIVE DAYTIME SLEEPINESS MARKET, BY DISTRIBUTION CHANNELS, 2018-2032 (USD BILLION)

TABLE 25 JAPAN: EXCESSIVE DAYTIME SLEEPINESS MARKET, BY DISEASES, 2018-2032 (USD BILLION)

TABLE 26 JAPAN: EXCESSIVE DAYTIME SLEEPINESS MARKET, BY TREATMENT, 2018-2032 (USD BILLION)

TABLE 27 JAPAN: EXCESSIVE DAYTIME SLEEPINESS MARKET, BY DISTRIBUTION CHANNELS, 2018-2032 (USD BILLION)

TABLE 28 CHINA: EXCESSIVE DAYTIME SLEEPINESS MARKET, BY DISEASES, 2018-2032 (USD BILLION)

TABLE 29 CHINA: EXCESSIVE DAYTIME SLEEPINESS MARKET, BY TREATMENT, 2018-2032 (USD BILLION)

TABLE 30 CHINA: EXCESSIVE DAYTIME SLEEPINESS MARKET, BY DISTRIBUTION CHANNELS, 2018-2032 (USD BILLION)

TABLE 31 INDIA: EXCESSIVE DAYTIME SLEEPINESS MARKET, BY DISEASES, 2018-2032 (USD BILLION)

TABLE 32 INDIA: EXCESSIVE DAYTIME SLEEPINESS MARKET, BY TREATMENT, 2018-2032 (USD BILLION)

TABLE 33 INDIA: EXCESSIVE DAYTIME SLEEPINESS MARKET, BY DISTRIBUTION CHANNELS, 2018-2032 (USD BILLION)

TABLE 34 AUSTRALIA: EXCESSIVE DAYTIME SLEEPINESS MARKET, BY DISEASES, 2018-2032 (USD BILLION)

TABLE 35 AUSTRALIA: EXCESSIVE DAYTIME SLEEPINESS MARKET, BY TREATMENT, 2018-2032 (USD BILLION)

TABLE 36 AUSTRALIA: EXCESSIVE DAYTIME SLEEPINESS MARKET, BY DISTRIBUTION CHANNELS, 2018-2032 (USD BILLION)

TABLE 37 SOUTH KOREA: EXCESSIVE DAYTIME SLEEPINESS MARKET, BY DISEASES, 2018-2032 (USD BILLION)

TABLE 38 SOUTH KOREA: EXCESSIVE DAYTIME SLEEPINESS MARKET, BY TREATMENT, 2018-2032 (USD BILLION)

TABLE 39 SOUTH KOREA: EXCESSIVE DAYTIME SLEEPINESS MARKET, BY DISTRIBUTION CHANNELS, 2018-2032 (USD BILLION)

TABLE 40 REST OF ASIA-PACIFIC: EXCESSIVE DAYTIME SLEEPINESS MARKET, BY DISEASES, 2018-2032 (USD BILLION)

TABLE 41 REST OF ASIA-PACIFIC: EXCESSIVE DAYTIME SLEEPINESS MARKET, BY TREATMENT, 2018-2032 (USD BILLION)

TABLE 42 REST OF ASIA-PACIFIC: EXCESSIVE DAYTIME SLEEPINESS MARKET, BY DISTRIBUTION CHANNELS, 2018-2032 (USD BILLION)

TABLE 43 REST OF THE WORLD: EXCESSIVE DAYTIME SLEEPINESS MARKET, BY DISEASES, 2018-2032 (USD BILLION)

TABLE 44 REST OF THE WORLD: EXCESSIVE DAYTIME SLEEPINESS MARKET, BY TREATMENT, 2018-2032 (USD BILLION)

TABLE 45 REST OF THE WORLD: EXCESSIVE DAYTIME SLEEPINESS MARKET, BY DISTRIBUTION CHANNELS, 2018-2032 (USD BILLION)

TABLE 46 MIDDLE EAST: EXCESSIVE DAYTIME SLEEPINESS MARKET, BY DISEASES, 2018-2032 (USD BILLION)

TABLE 47 MIDDLE EAST: EXCESSIVE DAYTIME SLEEPINESS MARKET, BY TREATMENT, 2018-2032 (USD BILLION)

TABLE 48 MIDDLE EAST: EXCESSIVE DAYTIME SLEEPINESS MARKET, BY DISTRIBUTION CHANNELS, 2018-2032 (USD BILLION)

TABLE 49 AFRICA: EXCESSIVE DAYTIME SLEEPINESS MARKET, BY DISEASES, 2018-2032 (USD BILLION)

TABLE 50 AFRICA: EXCESSIVE DAYTIME SLEEPINESS MARKET, BY TREATMENT, 2018-2032 (USD BILLION)

TABLE 51 AFRICA: EXCESSIVE DAYTIME SLEEPINESS MARKET, BY DISTRIBUTION CHANNELS, 2018-2032 (USD BILLION)

TABLE 52 LATIN AMERICA: EXCESSIVE DAYTIME SLEEPINESS MARKET, BY DISEASES, 2018-2032 (USD BILLION)

TABLE 53 LATIN AMERICA: EXCESSIVE DAYTIME SLEEPINESS MARKET, BY TREATMENT, 2018-2032 (USD BILLION)

LIST OF FIGURES

FIGURE 1 RESEARCH PROCESS

FIGURE 2 MARKET STRUCTURE FOR THE EXCESSIVE DAYTIME SLEEPINESS MARKET

FIGURE 3 MARKET DYNAMICS FOR THE EXCESSIVE DAYTIME SLEEPINESS MARKET

FIGURE 4 EXCESSIVE DAYTIME SLEEPINESS MARKET, SHARE (%), BY DISEASES, 2022

FIGURE 5 EXCESSIVE DAYTIME SLEEPINESS MARKET, SHARE (%), BY TREATMENT, 2022

FIGURE 6 EXCESSIVE DAYTIME SLEEPINESS MARKET, SHARE (%), BY DISTRIBUTION CHANNELS, 2022

FIGURE 7 EXCESSIVE DAYTIME SLEEPINESS MARKET, SHARE (%), BY REGION, 2022

FIGURE 8 NORTH AMERICA: EXCESSIVE DAYTIME SLEEPINESS MARKET, SHARE (%), BY REGION, 2022

FIGURE 9 EUROPE: EXCESSIVE DAYTIME SLEEPINESS MARKET, SHARE (%), BY REGION, 2022

FIGURE 10 ASIA-PACIFIC: EXCESSIVE DAYTIME SLEEPINESS MARKET, SHARE (%), BY REGION, 2022

FIGURE 11 REST OF THE WORLD: EXCESSIVE DAYTIME SLEEPINESS MARKET, SHARE (%), BY REGION, 2022

FIGURE 12 EXCESSIVE DAYTIME SLEEPINESS MARKET: COMPANY SHARE ANALYSIS, 2022 (%)

FIGURE 13 TEVA PHARMACEUTICAL INDUSTRIES LTD.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 14 TEVA PHARMACEUTICAL INDUSTRIES LTD.: SWOT ANALYSIS

FIGURE 15 GE HEALTHCARE : FINANCIAL OVERVIEW SNAPSHOT

FIGURE 16 GE HEALTHCARE : SWOT ANALYSIS

FIGURE 17 JAZZ PHARMACEUTICALS : FINANCIAL OVERVIEW SNAPSHOT

FIGURE 18 JAZZ PHARMACEUTICALS : SWOT ANALYSIS

FIGURE 19 COMPUMEDICS: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 20 COMPUMEDICS: SWOT ANALYSIS

FIGURE 21 FISHER & PAYKEL HEALTHCARE.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 22 FISHER & PAYKEL HEALTHCARE.: SWOT ANALYSIS

FIGURE 23 BIOPROJET: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 24 BIOPROJET: SWOT ANALYSIS

FIGURE 25 BMC MEDICAL CO. LTD.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 26 BMC MEDICAL CO. LTD.: SWOT ANALYSIS

FIGURE 27 AVADEL PHARMACEUTICALS PLC: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 28 AVADEL PHARMACEUTICALS PLC: SWOT ANALYSIS

FIGURE 29 CADWELL LABORATORIES INC. LTD : FINANCIAL OVERVIEW SNAPSHOT

FIGURE 30 CADWELL LABORATORIES INC. LTD : SWOT ANALYSIS

FIGURE 31 GLAXOSMITHKLINE PLC : FINANCIAL OVERVIEW SNAPSHOT

FIGURE 32 GLAXOSMITHKLINE PLC : SWOT ANALYSIS

FIGURE 33 BRAEBON MEDICAL CORPORATION: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 34 BRAEBON MEDICAL CORPORATION: SWOT ANALYSIS

FIGURE 35 PFIZER: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 36 PFIZER: SWOT ANALYSIS